BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35980949)

  • 41. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
    Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
    Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer.
    Jia X; Zhang L; Wu W; Zhang W; Wu C
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):246-253. PubMed ID: 27438512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
    Song Z; Yu X; Cheng G; Zhang Y
    J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
    Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
    Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
    Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
    Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
    Cai L; Duan J; Qian L; Wang Z; Wang S; Li S; Wang C; Zhao J; Zhang X; Bai H; Wang J
    Front Immunol; 2020; 11():527750. PubMed ID: 33324391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.
    Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
    Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
    J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion.
    Pan Y; Liu X; Zhang W; Wang W; Wang H; Luo L; Jia K; Shao C; Mao S; Qiu T; Ni J; Yu J; Wang L; Chen B; Xiong A; Gao G; Chen X; Wu F; Zhou C; Wu C; Ren S
    Lung Cancer; 2023 Jul; 181():107233. PubMed ID: 37201296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
    Hata T; Sakaguchi C; Hirano K; Kobe H; Ishida M; Nakano T; Tachibana Y; Tamiya N; Shiotsu S; Takeda T; Yamada T; Yokoyama T; Tsuchiya M; Nagasaka Y
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2475-2482. PubMed ID: 35737092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
    Liu Z; Zhao K; Wei S; Liu C; Zhou J; Gou Q; Wu X; Yang Z; Yang Y; Peng Y; Cheng Q; Liu L
    Oncoimmunology; 2020 May; 9(1):1758003. PubMed ID: 32923114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
    Noordhof AL; Damhuis RAM; Hendriks LEL; de Langen AJ; Timens W; Venmans BJW; van Geffen WH
    Lung Cancer; 2021 May; 155():163-169. PubMed ID: 33838467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark.
    Dalvi T; Nørgaard M; Fryzek JP; Movva N; Pedersen L; Pham Hansen H; Walker J; Midha A; Shire N; Boothman AM; Rigas J; Mellemgaard A; Rasmussen TR; Hamilton-Dutoit S; Cronin-Fenton D
    PLoS One; 2023; 18(4):e0284037. PubMed ID: 37040387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.
    Chang GC; Yang TY; Chen KC; Hsu KH; Huang YH; Su KY; Yu SL; Tseng JS
    Sci Rep; 2020 Dec; 10(1):21063. PubMed ID: 33273548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.